Quel est le prix pour AP Biosciences Inc (6945)

Le prix pour AP Biosciences Inc (6945) est $3.06

Quelle est la capitalisation boursière pour AP Biosciences Inc (6945)

La capitalisation boursière pour AP Biosciences Inc (6945) est $296.40M

AP Biosciences Inc (6945) Actions en Circulation

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

Année	Actions en circulation	Changez
Pas assez de données pour les dates fournies.

Année

Actions en circulation

Changez

Pas assez de données pour les dates fournies.

Entreprise	Actions en circulation	Différence	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Moderna, Inc. MRNA.US	396.00M	-	US
CSL Limited CSL.AX	478.91M	-	AU
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Actions en circulation

Différence

Pays